MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer

Sponsor:

Alliance for Clinical Trials in Oncology

Sponsor Study ID:

A032103

CTO #:

104042

NCT Number:

NCT05987241

Phase:

II/III

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Bladder

Study Objectives:

To compare the ctDNA clearance proportion at 12 weeks in patient enrolled in Cohort A treated with adjuvant nivolumab versus nivolumab + relatimab (phase 2 portion). To compare overall survival in patients enrolled in Cohort A treated with adjuvant nivolumab + relatlimab

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)